Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof

Abstract

The invention discloses the Neisseria meningitidis NMASP polypeptide, polypeptides derived therefrom (NMASP-derived polypeptides), nucleotide sequences encoding said polypeptides, and antibodies that specifically bind the NMASP polypeptide and / or NMASP-derived polypeptides. Also disclosed are prophylactic or therapeutic compositions, including immunogenic compositions, e.g., vaccines, comprising NMASP polypeptide and / or a NMASP-derived polypeptide. The invention additionally discloses methods of inducing a immune response to Neisseria meningitidis and Neisseria meningitidis NMASP polypeptide and an NMASP-derived polypeptide in animals.

Description

[0001] This application claims priority benefits of provisional U.S. application No. 60 / 098,685, filed Sep. 1, 1998, the entire disclosure of which is incorporated by reference herein.1. INTRODUCTION[0002] The present invention relates generally to a polypeptide of Neisseria meningitidis of approximately 40-55 kD referred to as "NMASP". The invention encompasses an isolated or purified NMASP polypeptide and polypeptides, including fragments, derived therefrom (NMASP-derived polypeptides), and methods of making thereof. The invention also encompasses antibodies, including cytotoxic or bactericidal antibodies, that specifically bind the NMASP polypeptide, NMASP-derived polypeptides and / or fragments thereof. The invention further encompasses immunogenic, prophylactic or therapeutic compositions, including vaccines, that comprise NMASP polypeptide, NMASP-derived polypeptides and / or fragments thereof. The invention additionally provides methods of inducing an immune response to Neisseria...

AI Technical Summary

Problems solved by technology

Unlike Hib infections which are basically sporadic limited outbreaks, epidemics of meningococcal disease occur regularly throughout the world and cause great suffering and death.

Once colonization is established, the organism can invade the underlying endothelium and gain entry into the circulatory system where it causes a rapid, fulminate meningococcemia and / or progresses. to the cerebrospinal fluid to cause an often fatal meningitis.

The emergence of sulfonamide-resistant organisms in military recruits spurred the development of CPS vaccines against serogroups A, C, and W. While these vaccines are highly immunogenic and effective in adults, the immune response elicited in infants is minimal and of short duration, due primarily to the fact that the very young respond poorly to T-cell-independent antigens like the CPS immunogen.

While outer membrane bleb-based and outer membrane vesicle-based (OMVs) vaccines are able to elicit at least some degree of bactericidal antibodies and mild cross-strain protection in young children, these vaccines are difficult and problematic to prepare which renders them impractical as commercial vaccines.

Due to the antigenic variation among the major outer membrane proteins of the meningococci, these proteins confer limited cross-strain protection and are thus not suitable as cross-protective subunit vaccines.

Images